A congenital heart disease is a problem in the structure of the heart that is present at birth. The factors driving the growth of the global congenital heart disease market are rising prevalence of congenital heart disease and rise in adoption of minimally invasive procedures. Further, large number of dominating market players, growing demand for catheterization and application of cardiac biomarkers in congenital heart disease treatment are also considered as a major factor for driving the growth of the global congenital heart disease market during forecast period.

In 2018, the global Congenital Heart Disease market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025. This report focuses on the global Congenital Heart Disease status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Congenital Heart Disease development in United States, Europe and China. The key players covered in this study

Abbott Diagnostics
Array BioPharma
AstraZeneca
Becton Dickinson
BG Medicine
Bio-Rad
Boston Scientific
Covance
Critical Diagnostics
Roche
GSK
Janssen Pharmaceuticals
Medtronic
Merck
Mylan
Market segment by Type, the product can be split into
Medications
Implantable heart devices
Catheter procedures
Open-heart surgery
Heart transplant
Market segment by Application, split into
Hospitals and clinics
Diagnostic centres
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Congenital Heart Disease status, future forecast, growth opportunity, key market and key players.
To present the Congenital Heart Disease development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Congenital Heart Disease are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
1.4.2 Medications
1.4.3 Implantable heart devices
1.4.4 Catheter procedures
1.4.5 Open-heart surgery
1.4.6 Heart transplant
1.5 Market by Application
1.5.1 Global Congenital Heart Disease Market Share by Application (2014-2025)
1.5.2 Hospitals and clinics
1.5.3 Diagnostic centres
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Congenital Heart Disease Market Size
2.2 Congenital Heart Disease Growth Trends by Regions
2.2.1 Congenital Heart Disease Market Size by Regions (2014-2025)
2.2.2 Congenital Heart Disease Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Congenital Heart Disease Market Size by Manufacturers
3.1.1 Global Congenital Heart Disease Revenue by Manufacturers (2014-2019)
3.1.2 Global Congenital Heart Disease Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Congenital Heart Disease Market Concentration Ratio (CR5 and HHI)
3.2 Congenital Heart Disease Key Players Head office and Area Served
3.3 Key Players Congenital Heart Disease Product/Solution/Service
3.4 Date of Enter into Congenital Heart Disease Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Congenital Heart Disease Market Size by Type (2014-2019)
4.2 Global Congenital Heart Disease Market Size by Application (2014-2019)

5 United States
5.1 United States Congenital Heart Disease Market Size (2014-2019)
5.2 Congenital Heart Disease Key Players in United States
5.3 United States Congenital Heart Disease Market Size by Type
5.4 United States Congenital Heart Disease Market Size by Application

6 Europe
6.1 Europe Congenital Heart Disease Market Size (2014-2019)
6.2 Congenital Heart Disease Key Players in Europe
6.3 Europe Congenital Heart Disease Market Size by Type
6.4 Europe Congenital Heart Disease Market Size by Application

7 China
7.1 China Congenital Heart Disease Market Size (2014-2019)
7.2 Congenital Heart Disease Key Players in China
7.3 China Congenital Heart Disease Market Size by Type
7.4 China Congenital Heart Disease Market Size by Application

8 Japan
8.1 Japan Congenital Heart Disease Market Size (2014-2019)
8.2 Congenital Heart Disease Key Players in Japan
8.3 Japan Congenital Heart Disease Market Size by Type
8.4 Japan Congenital Heart Disease Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Congenital Heart Disease Market Size (2014-2019)
9.2 Congenital Heart Disease Key Players in Southeast Asia
9.3 Southeast Asia Congenital Heart Disease Market Size by Type
9.4 Southeast Asia Congenital Heart Disease Market Size by Application

10 India
10.1 India Congenital Heart Disease Market Size (2014-2019)
10.2 Congenital Heart Disease Key Players in India
10.3 India Congenital Heart Disease Market Size by Type
10.4 India Congenital Heart Disease Market Size by Application

11 Central & South America
11.1 Central & South America Congenital Heart Disease Market Size (2014-2019)
11.2 Congenital Heart Disease Key Players in Central & South America
11.3 Central & South America Congenital Heart Disease Market Size by Type
11.4 Central & South America Congenital Heart Disease Market Size by Application

12 International Players Profiles
12.1 Abbott Diagnostics
12.1.1 Abbott Diagnostics Company Details
12.1.2 Company Description and Business Overview
12.1.3 Congenital Heart Disease Introduction
12.1.4 Abbott Diagnostics Revenue in Congenital Heart Disease Business (2014-2019)
12.1.5 Abbott Diagnostics Recent Development
12.2 Array BioPharma
12.2.1 Array BioPharma Company Details
12.2.2 Company Description and Business Overview
12.2.3 Congenital Heart Disease Introduction
12.2.4 Array BioPharma Revenue in Congenital Heart Disease Business (2014-2019)
12.2.5 Array BioPharma Recent Development

12.3 AstraZeneca
12.3.1 AstraZeneca Company Details
12.3.2 Company Description and Business Overview
12.3.3 Congenital Heart Disease Introduction
12.3.4 AstraZeneca Revenue in Congenital Heart Disease Business (2014-2019)
12.3.5 AstraZeneca Recent Development

12.4 Becton Dickinson
12.4.1 Becton Dickinson Company Details
12.4.2 Company Description and Business Overview
12.4.3 Congenital Heart Disease Introduction
12.4.4 Becton Dickinson Revenue in Congenital Heart Disease Business (2014-2019)
12.4.5 Becton Dickinson Recent Development

12.5 BG Medicine
12.5.1 BG Medicine Company Details
12.5.2 Company Description and Business Overview
12.5.3 Congenital Heart Disease Introduction
12.5.4 BG Medicine Revenue in Congenital Heart Disease Business (2014-2019)
12.5.5 BG Medicine Recent Development

12.6 Bio-Rad
12.6.1 Bio-Rad Company Details
12.6.2 Company Description and Business Overview
12.6.3 Congenital Heart Disease Introduction
12.6.4 Bio-Rad Revenue in Congenital Heart Disease Business (2014-2019)
12.6.5 Bio-Rad Recent Development

12.7 Boston Scientific
12.7.1 Boston Scientific Company Details
12.7.2 Company Description and Business Overview
12.7.3 Congenital Heart Disease Introduction
12.7.4 Boston Scientific Revenue in Congenital Heart Disease Business (2014-2019)
12.7.5 Boston Scientific Recent Development

12.8 Covance
12.8.1 Covance Company Details
12.8.2 Company Description and Business Overview
12.8.3 Congenital Heart Disease Introduction
12.8.4 Covance Revenue in Congenital Heart Disease Business (2014-2019)
12.8.5 Covance Recent Development

12.9 Critical Diagnostics
12.9.1 Critical Diagnostics Company Details
12.9.2 Company Description and Business Overview
12.9.3 Congenital Heart Disease Introduction
12.9.4 Critical Diagnostics Revenue in Congenital Heart Disease Business (2014-2019)
12.9.5 Critical Diagnostics Recent Development

12.10 Roche
12.10.1 Roche Company Details
12.10.2 Company Description and Business Overview
12.10.3 Congenital Heart Disease Introduction
12.10.4 Roche Revenue in Congenital Heart Disease Business (2014-2019)
12.10.5 Roche Recent Development

12.11 GSK
12.12 Janssen Pharmaceuticals
12.13 Medtronic
12.14 Merck
12.15 Mylan

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
   15.1.1.1 Research Programs/Design
   15.1.1.2 Market Size Estimation
   12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
   15.1.2.1 Secondary Sources
   15.1.2.2 Primary Sources
15.2 Disclaimer